SUMMARY Twenty-eight patients with heart failure caused by congestive cardiomyopathy, which had been diagnosed according to the criteria of Goodwin and Oakley, were treated with beta-blocking agents for six to 62 months, except for four patients who died within two months. Repeated non-invasive investigations were performed before and during treatment as well as exercise tests and chest x-rays. The echocardiographic and pulse curve findings indicated an improvement in systolic and diastolic myocardial function. The ejection fraction increased from 0-32±0-02 to 0-42±0-04, and the third heart sound amplitude and rapid filling wave were significantly reduced. The functional classification improved in 15 patients while in 12 patients it remained unchanged and in one it deteriorated. During follow-up, 10 patients died, most of them suddenly. The mortality was lower than expected in this severely ill group of patients.
Patients with congestive cardiomyopathy (COCM) are usually treated with digitalis and diuretics for relief of heart failure. The prognosis is considered poor when heart failure is severe despite optimal conventional treatment.'-4 Temporary improvement of heart failure has been reported after very long periods of bed rest.5 In 1975 Waagstein et al.6 reported from this clinic that seven patients with COCM and heart failure showed improved myocardial function and exercise capacity on chronic beta-receptor blockade.
This study was undertaken to evaluate further the effects of beta-blockade in patients with COCM. Twenty-eight patients were treated with betablocking agents for six to 16-year-old girl (case 20) , deteriorated during the first two weeks of observation and a beta-blocker was given because of concern for her condition. The first eight patients started on beta-blockade immediately after the observation period and then were followed up regularly. Five of these patients the 16 patients, placebo treatment was continued for three months. Two patients (cases 11 and 16) were given beta-blockers before the end of this three-month period, because of severe deterioration in their condition, and three others continued on placebo for six months to enable one to assess the stability of theirs.
BETA-BLOCKER TREATMENT
In six of the seven patients first treated with beta blockers the cardioselective agent practolol was used. It was thought on theoretical grounds that a cardioselective drug, with less influence on peri- were included in our previous paper.6 For the remaining 20 patients (cases 9 to 28) the intention was, after the initial observation period, to give all of them single-blind placebo treatment for three months before starting beta-blockade. However, this plan could only be followed in 16 patients. Four patients (cases 17, 20,24, and 27) , because their condition was considered to be life-threatening, were given beta-blockers as above and no placebo. The procedure allowed the placebo period to be prolonged if, during it, signs of haemodynamic improvement could be seen, as judged by the noninvasive investigations mentioned above. (cases 9, 11, and 12) in this group, all patients were changed from alprenolol to metoprolol treatment within six months. With great differences in response between patients, difficulties were anticipated in the evaluation of the importance of cardioselectivity and the last 12 patients included in the study all received metoprolol from the start of treatment. The usual initial dose of metoprolol was 25 mg a day which could be increased by 25 mg each day or every second day. In three patients (cases 17, 20, and 28) whose clinical condition was extremely poor, the initial dose was 12-5 mg a day and it was increased slowly, by 12-5 to 25 mg every second or third day. Systolic blood pressure and resting heart rate were measured five to six times a day, the aim of treatment being a blood pressure above 100 mmHg and a heart rate of 70 beats per minute. The duration of beta-blocker treatment, the initial drug used, and the final drug and dosage are given in Table 1 for all of the patients.
Methods

NON-INVASIVE INVESTIGATIONS
Investigations were performed according to a standard procedure in all patients, usually at the same time each day. Because it was possible to perform these investigations on several occasions during the follow-up period, myocardial function could be repeatedly assessed. All data were summarised in a report which included both the diagnosis and an evaluation of the severity of myocardial dysfunction. The diagnosis of congestive cardiomyopathy was based on the finding of a dilated left ventricle with symmetrically depressed systolic function, without hypokinetic areas to suggest coronary artery disease. The severity was assessed by a combination of direct measurements of pump function (EF and mean VCF), and indirect evidence of forward and backward failure.
The principles used in assessing the degree of myocardial dysfunction are based on earlier experience and are described below. 
Results
CLINICAL FINDINGS
Twenty-eight patients were studied before treatment, and with up to 62 months of chronic beta blockade. As can be seen from Table 1 , the duration of symptoms before treatment varied from three to 172 months. The treatment period equalled or exceeded six months in 24 patients, and was shorter than this in four patients who died early. In all patients, a low dose of a beta-blocking agent was given initially because of the risk of inducing heart failure. The maintenance doses used are shown in Table 1 . From IV  III  III  III   II   II  II  II  2  III  III  III  III t  3  III  III  III  III  III  III III  III  4  III  III  III  II  II  II  II  II  5  IV  III III III III III III t  6  III  III  III  III III  III IV  III  7  III  III  III  III  III  III  III t  8  III  III  III  III   II   II  III  III  9  III  III t  10  III  IV  II   II   I  I  I  II  11  IV  t  12  III  III t  13  III  III  III  II  II  II  II  II  14  III  III  III  II  II  II  II  II  15  III  III  III  III  III  III III III  16  IV  III  III  III  II  II  II  t  17  IV  III  II  II  II  II  I  18  III  III  III  III  III  19  III  III  III  III  III  III  20  IV  III  II  I  I   I   21  III  III  III  III t  22  III  III  II  II  I  I  23  II  II  I  I  24  III  t  25  III  III  III  III  26  III  III  III  II  27  IV  II  II  II  28  IV  III  III  III t dead.
and five of these returned to full-time work (cases 10, 16, 17, 20, and 22) . Three of the patients showed a dramatic improvement (cases 1, 17, and 20) in their clinical condition, and two of those (cases 17 and 20) are described in detail in the case reports while case 1 is described elsewhere."3 During the follow-up period 10 patients died, seven of them without showing clinical deterioration after the start of beta-blockade (cases 2, 7, 8, 9, 12, 21, and 24; Table 2 ). Two patients died after their clinical condition had improved as a result of more than two years' treatment (cases 5 and 16). One patient deteriorated gradually after the start of beta-blockade, treatment was discontinued after five weeks, and she died one week later (case 11). In none of the other nine patients was the addition of beta-blockade to their conventional treatment considered to have increased their cardiac decompensation. Seven of the patients died suddenly and three died from cardiac decompensation. Four of the 10 patients died within three months of starting beta-blockade, and three of these died suddenly (cases 10, 12, and 24).
Case reports
The clinical course is illustrated by the following three cases.
CASE 17
This was a 16-year-old boy who developed a throat infection in March 1975. He recovered in a week but 10 days later he again became febrile and a chest x-ray showed cardiomegaly (800 ml/m2) and bronchopneumonia. He was treated with digoxin and frusemide at another centre for one month. Repeated blood cultures were negative and his fever disappeared in a few days. The patient's clinical condition remained unchanged during the first month as did his cardiac enlargement. He was readmitted to the hospital three-and-a-half months after the first admission, giving a one-week history of increasing exertional dyspnoea and gastrointestinal discomfort. He was referred to our hospital 10 days later, four months after cardiomegaly was first noted. On admission he was breathless at rest. Auscultation showed a third heart sound, gallop rhythm, and an apical systolic murmur. The blood pressure was 110/80 mmHg and the heart rate 120 beats/min. Investigations (Table 3) of 0 50, and LVET of 90 per cent, a faint third heart sound, and an apical systolic murmur. The patient had a normal working capacity.
CASE 20
This was a 17-year-old girl who had had bronchial asthma since childhood. Despite this, she had worked as a groom for 10 months, and was receiving treatment with terbutaline by inhalation. For three months before admission, she had suffered from increasing exertional dyspnoea, and for the last month from epigastric discomfort. On admission in May 1976 she was dyspnoeic but without peripheral oedema or pulmonary rales. There was significant hepatic enlargement. On auscultation a third heart sound and a weak apical systolic murmur could be heard. The heart rate was 140 beats/min (LVEDD 741 cm, EF 0 35, LVET 55%). Treatment with digoxin and frusemide was started. Five days later the patient's condition had improved but she was still in functional group IV. Investigations ( Fig. 1 ; (Table   3 ) an LVEDD of 7-4 cm, an EF of 0 30 with tiny contractions, and an LVET of 66 per cent. She was considered to have very severe COCM. Cardiac catheterisation showed a heart rate of 122, an arterial pressure of 128/100 mmHg, a pulmonary artery pressure of 59/35 mmHg, and a right atrial pressure of 16 mmHg; the cardiac index was 1 6 1/ min per m2 and stroke index 13 ml/m2. After 15 mg metoprolol intravenously, the corresponding pressures were 108/83, 47/30, and 14 mmHg, the cardiac index was 1-3, and the stroke index 12. She was therefore given metoprolol orally 25 mg twice daily in addition to digitalis and frusemide. A distinct improvement was noted with a reduction in her dyspnoea. The blood pressure was unchanged, the heart rate decreased to 90 to 100 beats/min, and the extra sounds became much quieter. The metoprolol dosage was increased to 50 mg twice daily, and the patient improved further so that she could walk freely without discomfort. On 20 October she developed left-sided chest pain and was noted to have a temperature for two days. She showed no clinical signs of heart failure thereafter. Nine days later the patient was found dead. Necropsy disclosed a dilated heart of 550 g. The coronary arteries showed no stenosis and there were no signs of myocardial ischaemia. Two small pulmonary emboli were found.
Non-invasive findings
Forty-six studies were performed before, and 53 after, the start of beta-receptor blockade in 23 patients. Four patients were not reinvestigated before they died (cases 9, 11, 12, and 24) and one patient (case 5) was not investigated before the start of treatment. The observation period was divided into four parts; 1 to 6, 7 to 12, 13 to 24, and greater than 24 months after the start of beta blockade. If a patient underwent more than one investigation during the same period, the mean values were taken. The results are shown in Fig. 3 and 4.
From Fig. 3A and Table 3 it can be seen that the LVEDD decreased in 12 patients. In three patients the LVEDD increased (cases 3, 6, and 8), and in 11 patients it remained essentially unchanged. The EF (Fig. 3B) (Fig. 3D) .
The amplitude of the third heart sound, measured from the apical phonocardiogram, decreased in most patients (Fig. 4A) . However, three of the patients (cases 18, 21, and 27) showed an increase. Overall, the amplitude of the third heart sound decreased from 11 +2 to 5 ± 1 mm (p <O0-02) and the amplitude of the fourth heart sound showed similar changes, with a decrease in 12 patients and an unchanged or increased amplitude in four patients (Fig. 4B) . The RFW/H ratio decreased significantly overall in all observation periods (Fig. 4C) group.bmj.com on July 7, 2017 -Published by http://heart.bmj.com/ Downloaded from 17). The third heart sound amplitude and the RFW always showed corresponding changes. A reduction of these variables correlated with an improvement in the clinical condition and this occurred usually in the first two weeks. This correlation can be seen in the comparison of changes in functional groups (Table 2 and Fig. 4A-D) . In three patients (cases 18, 21, and 27) the EF and LVET were either unchanged or reduced and the third heart sound and RFW increased. Cases 18 and 21 complained of gastrointestinal discomfort and showed poor motivation for treatment. They had no problems with the medication during inpatient treatment, but their compliance as outpatients was questionable. Case 27 deteriorated during the first four months on metoprolol 50 mg twice a day. On ..A group.bmj.com on July 7, 2017 -Published by http://heart.bmj.com/ Downloaded from investigation four months after the start of beta blockade, the third heart sound had increased t( 50 mm and the RFW/H ratio to 110 per cent (sic while the EF was reduced from 0-29 to 019 The patient's clinical condition became critical an' he developed severe peripheral oedema which dic not respond to increased doses of frusemide. Ir desperation, the metoprolol dosage was increasec to 100 mg twice a day. The patient improve dramatically in the following two weeks, periphera oedema and dyspnoea at rest disappearing. Furthe investigation showed that the third heart sounc was then reduced to 5 mm and the RFW/H rati( to 6 per cent. The mean values for the last tw( studies, both performed within six months of th start of beta-blockade, are shown in Table 3 anc Fig. 3 and 4 . The figures do not illustrate th4 observed changes in this patient.
The relation of heart rate to the other variable in Fig 3 and 4 a900 amplitude correlated weakly with the heart rate change (r=0-59) (Fig. 6 ).
HEART VOLUME Chest x-ray film was taken in all patients before and in 21 patients during beta-blocker treatment.
The heart volumes are shown in Fig. 5A . The volume decreased significantly in eight patients, with a distinct increase in three patients. The remaining 10 patients showed no definite changes. In the two patients with the largest hearts, a distinct reduction was seen. 
Invasive investigation
Mainly non-invasive techniques were used in this study for the diagnosis of COCM and assessment of the severity of the disease and the results of treatment. However, in four of the first patients treated, cardiac catheterisation was performed on two occasions, separated by an interval of two to 13 months (cases 1, 2, 6, and 7). These investigations formed part of the routine clinical assessment and were not related to the study design. The results, however, support the findings from the non-invasive investigations (Fig. 7) . Cardiac output increased in three of these four patients and this was especially pronounced in case 1 who showed an increase from 1-9 to 5-1 1/min. The heart rate was reduced in all patients but one. in whom the most obvious increase in cardiac output occurred. The brachial artery and systolic blood pressure increased in all patients. In nine patients left ventricular angiography and echocardiography were performed within a space of one week. The EF calculated from these investigations correlated well (r=0.92) (Fig. 8) .
Discussion
All the patients in this study were diagnosed as having congestive cardiomyopathy, according to the criteria proposed by Goodwin and Oakley.7 Coronary artery disease was excluded by history, and by coronary angiography in 14 patients. The diagnosis and the assessment of the severity of the disease were based upon a series of non-invasive investigations which included phonocardiograms, apex cardiograms, pulse curves from the carotid artery, jugular vein, and liver, and echocardiograms. The advantages of this non-invasive programme were that it gave information on the severity of myocardial dysfunction and that it could be repeated several times during follow-up. Measure- Heart rate Fig. 6 Relation between heart rate and amplitude of third heart sound, before (0) and during (0) The improvement in cardiac function and in the patients' general condition with beta-blockade could not be explained on the basis of spontaneous improvement in selected subjects. All patients referred to this centre suspected of having COCM have been investigated and all those in whom the diagnosis was confirmed were included in the study. Only patients with evidence of grossly impaired myocardial function (generally in functional group III or IV, according to the New York Heart Association criteria) were given chronic betablocker treatment. In a separate study,'3 the effect of withdrawal of beta-blockade has been investigated in 13 of the patients reported here. It was found that withdrawal of treatment caused a deterioration of myocardial function and in several of the patients led to a distinct exacerbation of their symptoms. This strongly supports the view that the improvement seen in the patients in this study is related to the beta-blocker treatment.
Phaeochromocytoma may induce cardiomyopathy with heart failure,23 24 clearly showing a connection between high concentrations of catecholamines and this condition. In the treatment of these patients, beta-blocking agents are used to protect the myocardium from the influence of catecholamines until the tumour is removed sugically. Thus, it may be concluded that other clinical observations, besides our own, together with animal data, support the hypothesis that catecholamines are involved in the development of some forms of cardiomyopathy and that reduced sympathetic activity by beta-receptor blockade can prevent the progress of the condition. This view is supported by our present findings of a beneficial effect of chronic beta blockade on COCM. The suggested role of catecholamines and sympathetic activity in the development of the condition remains to be proved, and studies are in progress to find out whether there is primary sympathetic overactivity in patients with COCM or an increased sensitivity to sympathetic stimulation.
This study clearly demonstrates that chronic beta-receptor blockade may cause a significant improvement in myocardial function and relief of symptoms in patients with COCM. The improvement occurs in patients with moderate as well as severe heart failure. The patients responding best to beta-blockade could not be predicted by the methods used and it is therefore suggested that beta-receptor blockade should be added to conventional treatment with digitalis and diuretics in all patients with COCM. More experience of this treatment regimen, however, is needed in order to allow identification of the patients most suitable for it.
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